McKesson Corporation MCK SPX

Healthcare · Medical Distribution · United States

https://www.mckesson.com

McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: North American Pharmaceutical, Oncology & Multispecialty, Prescription Technology Solutions, and Medical-Surgical Solutions. The company distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products; delivers products to retail pharmacies, hospitals, long-term care centers, clinics, and institutions; and provides logistics and distribution services for manufacturers. It also provides consulting, outsourcing, technological, and other services, as well as sells financial, operational, and clinical solutions to pharmacies; gene therapy with InspiroGene, practice consulting, and vaccine distribution services; and technology solutions, as well as research, insights, technologies, and services to improve cancer and specialty care. In addition, the company helps in solving medication access, affordability, and adherence challenges for patients by working across healthcare to connect patients, pharmacies, providers, pharmacy benefit managers, health plans, and biopharma companies. Further, it offers technology services, which includes electronic prior authorization, prescription price transparency, benefit insight, dispensing support services, patient enrollment, third-party logistics, and wholesale distribution support; medical-surgical supplies, laboratory equipment, pharmaceutical distribution, logistics, and other services to healthcare providers, including physician offices, surgery centers, and hospital reference labs, nursing homes, hospice and home health care agencies, government facilities ,and online marketplaces and retailers. McKesson Corporation was founded in 1833 and is headquartered in Irving, Texas.

Market & Price

Market Cap

$89.24B

Current Price

$742.44

High / Low (52W)

$995.69 / $657.06

Beta

0.35

Valuation

Stock P/E

19.34

Industry PE

23.65

Forward P/E

14.75

PEG Ratio

1.45

Book Value

$-18.10

Price to Book

-41.02

P/S

0.22

EV/EBITDA

13.86

Dividend Yield

0.44%

Profitability & Returns

ROCE

42.13%

ROE

ROA

4.99%

Profit Margin

1.18%

Op Margin

2.21%

EPS (Latest Qtr)

$9.59

EPS (TTM)

$38.38

Balance Sheet & Liquidity

Debt/Equity

Quick Ratio

0.48

Current Ratio

0.85

Debt

$8.79B

Total Assets

$82.32B

Current Assets

$57.21B

Working Capital

$-9.81B

Ownership

Promoter Holding

0.06%

Chg in Prom Hold

FII / Inst Holding

93.50%

Chg in FII Hold

-0.01%

Financial Snapshot

Enterprise Value

$95.39B

Total Revenue (TTM)

$403.43B

EBITDA

$6.88B

Free Cash Flow

$5.66B

Operating Cash Flow

$6.15B

Shares Outstanding

120.20M

Gross Margin

3.60%

Payout Ratio

8.26%

Growth (CAGR)

Revenue 5Y

13.39%

Profit 5Y

10.18%

Revenue (YoY)

6.00%

Earnings (YoY)

37.20%

PROS

Healthy ROCE of 42.1%.
Compounding revenue at 13.4% over 5 years.
Profit CAGR of 10.2% over 5 years.
Generates positive free cash flow.
In a confirmed uptrend (50-DMA above 200-DMA).

CONS

Trading 25.4% below its 52-week high.

* The pros and cons are auto-generated from financial metrics.

Price Chart

Robinhood TradingView StockAnalysis

Fundamental Growth

Period: Metric:

Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).

Peer comparison

Peer companies in the same sector (Healthcare).

#	Name	CMP $	P/E	Mkt Cap	Div Yld %	ROCE %	ROE %	Rev CAGR 5Y %	Profit CAGR 5Y %
1	MCK McKesson Corporation SPX	742.44	19.34	$89.24B	0.44%	42.13%	-	13.39%	10.18%
2	LLY Eli Lilly and Company SPX	1,105.00	39.21	$985.37B	0.63%	38.44%	107.46%	31.69%	48.96%
3	JNJ Johnson & Johnson SPX	225.33	26.11	$542.42B	2.38%	23.13%	26.42%	5.60%	14.32%
4	UNH UnitedHealth Group Incorporated SPX	380.31	28.66	$345.38B	2.32%	9.60%	12.18%	11.35%	-15.69%
5	MRK Merck & Co., Inc. SPX	118.72	33.44	$293.22B	2.86%	20.66%	18.94%	3.12%	7.93%
6	TMO Thermo Fisher Scientific Inc. SPX	492.51	27.11	$183.03B	0.38%	9.17%	13.52%	-0.27%	-1.19%
7	AMGN Amgen Inc. NDXSPX	336.79	23.42	$181.77B	2.99%	18.02%	101.32%	11.77%	5.58%
8	GILD Gilead Sciences, Inc. NDXSPX	134.43	18.29	$166.90B	2.44%	22.92%	43.36%	2.57%	22.83%
9	ISRG Intuitive Surgical, Inc. NDXSPXAI	424.64	51.53	$150.39B	-	15.96%	17.23%	17.39%	29.26%

Quarterly Results

Figures in USD.

Metric	Sep 2015	Dec 2015	Mar 2016	Jun 2016	Sep 2016	Dec 2016	Mar 2017	Jun 2017	Sep 2017	Dec 2017	Mar 2018	Jun 2018	Sep 2018	Dec 2018	Mar 2019	Jun 2019	Sep 2019	Dec 2019	Mar 2020	Jun 2020	Sep 2020	Dec 2020	Mar 2021	Jun 2021	Sep 2021	Dec 2021	Jun 2022	Sep 2022	Dec 2022	Jun 2023	Sep 2023	Dec 2023	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
Revenue	-	-	-	-	-	-	-	51.05B	52.06B	53.62B	51.63B	52.61B	53.08B	56.21B	52.43B	55.73B	57.62B	59.17B	58.53B	55.68B	60.81B	62.60B	59.14B	62.67B	66.58B	68.61B	67.15B	70.16B	70.49B	74.48B	77.22B	80.90B	79.28B	-	-	90.82B	97.83B	103.15B	106.16B	96.30B
Cost of Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	87.18B	94.55B	99.61B	102.47B	92.25B
Gross Profit	2.84B	2.87B	2.85B	2.91B	2.76B	2.81B	2.80B	2.56B	2.83B	2.71B	3.08B	2.78B	2.80B	2.97B	3.20B	2.79B	2.87B	3.03B	3.34B	2.70B	3.00B	3.15B	3.30B	3.03B	3.35B	3.43B	3.02B	3.10B	3.17B	3.02B	3.07B	3.15B	3.15B	-	-	3.64B	3.28B	3.54B	3.69B	4.04B
Operating Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1.98B	2.20B	2.07B	2.03B	1.80B
Operating Income	954.00M	920.00M	-	972.00M	580.00M	831.00M	-	633.00M	239.00M	834.00M	-	83.00M	689.00M	683.00M	-	634.00M	626.00M	360.00M	-	678.00M	634.00M	-7.36B	-	568.00M	539.00M	298.00M	1.04B	1.12B	1.24B	1.10B	951.00M	642.00M	1.03B	-	-	1.66B	1.08B	1.47B	1.66B	2.25B
EBITDA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1.71B	1.26B	1.66B	1.88B	2.38B
Interest Expense	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	45.00M	49.00M	74.00M	63.00M	61.00M
Pretax Income	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1.51B	1.05B	1.40B	1.63B	2.12B
Tax Provision	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	209.00M	220.00M	232.00M	380.00M	270.00M
Net Income	617.00M	634.00M	431.00M	542.00M	307.00M	633.00M	3.59B	309.00M	1.00M	903.00M	-1.15B	-138.00M	499.00M	469.00M	-796.00M	423.00M	-730.00M	186.00M	1.02B	444.00M	577.00M	-6.23B	666.00M	486.00M	267.00M	-7.00M	768.00M	926.00M	1.08B	958.00M	664.00M	589.00M	915.00M	-	-	1.26B	784.00M	1.11B	1.19B	1.68B
Diluted EPS	2.63	2.73	1.88	2.38	1.34	2.85	16.76	1.45	0.01	4.33	-5.58	-0.68	2.51	2.40	-4.17	2.24	-3.99	1.03	5.85	2.72	3.54	-39.03	4.15	3.07	1.71	-0.04	5.26	6.42	7.66	7.02	4.92	4.42	7.00	-	6.95	10.01	6.25	8.92	9.59	-

Profit & Loss (Annual)

Figures in USD.

Metric	Mar 2008	Mar 2009	Mar 2010	Mar 2011	Mar 2012	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Revenue	-	-	-	-	-	-	-	-	-	198.53B	208.36B	214.32B	231.05B	238.23B	-	276.71B	308.95B	359.05B	403.43B
Cost of Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	264.35B	296.12B	345.73B	388.88B
Gross Profit	5.01B	5.38B	5.68B	5.97B	6.40B	6.88B	8.35B	11.41B	11.42B	11.27B	11.18B	11.75B	12.02B	12.15B	-	12.36B	12.83B	13.32B	14.55B
Operating Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	7.78B	8.66B	8.51B	8.10B
Operating Income	1.48B	1.20B	2.01B	1.82B	2.12B	2.35B	2.44B	2.97B	3.54B	7.12B	762.00M	886.00M	2.49B	-5.04B	-	4.58B	4.17B	4.82B	6.45B
EBITDA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	5.49B	4.68B	5.26B	7.18B
Interest Expense	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	248.00M	252.00M	265.00M	247.00M
Pretax Income	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	4.63B	3.79B	4.36B	6.20B
Tax Provision	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	905.00M	629.00M	878.00M	1.10B
Net Income	-	823.00M	1.26B	1.20B	1.40B	1.34B	1.26B	1.48B	2.26B	5.07B	67.00M	34.00M	900.00M	-4.54B	-	3.56B	3.00B	3.29B	4.76B
Diluted EPS	3.32	2.95	4.62	4.57	5.59	5.59	5.41	6.27	9.70	22.73	0.32	0.17	4.95	-28.26	-	25.03	22.39	25.72	38.38
R&D Expense	347.00M	364.00M	376.00M	407.00M	402.00M	433.00M	457.00M	392.00M	392.00M	341.00M	125.00M	71.00M	96.00M	-	-	-	-	-	-

Compounded Sales Growth

5 Years:	13.39%
1 Year:	6.00%

Compounded Profit Growth

5 Years:	10.18%
1 Year:	37.20%

Stock Price Performance

1 Year:	+3.59%
6 Months:	-16.37%
3 Months:	-24.74%
1 Month:	-9.75%

Balance Sheet (Annual)

Figures in USD.

Metric	Mar 2007	Mar 2008	Mar 2009	Mar 2010	Mar 2011	Mar 2012	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Total Assets	-	-	25.27B	28.19B	30.89B	33.09B	34.79B	51.76B	53.87B	56.52B	60.97B	60.38B	59.67B	61.25B	65.02B	-	62.32B	67.44B	75.14B	82.32B
Current Assets	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	44.29B	47.97B	55.40B	57.21B
Cash & Equivalents	1.95B	1.36B	2.11B	3.73B	3.61B	3.15B	2.46B	4.19B	5.34B	4.05B	2.78B	2.67B	2.98B	4.01B	6.28B	-	4.68B	4.58B	5.69B	3.98B
Inventory	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	19.69B	21.14B	23.00B	24.21B
Receivables	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	17.16B	19.44B	22.28B	24.25B
Total Liabilities	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	63.81B	69.04B	76.83B	83.16B
Current Liabilities	-	-	15.61B	17.01B	18.73B	21.69B	21.36B	29.61B	33.50B	35.07B	35.61B	36.69B	37.63B	42.62B	44.10B	-	47.96B	52.36B	61.60B	67.02B
Long Term Debt	-	-	-	2.29B	3.59B	3.07B	-	-	-	-	-	-	-	-	-	-	4.63B	5.58B	4.46B	5.26B
Total Debt	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	7.29B	7.39B	7.39B	8.61B
Total Equity	-	-	6.19B	7.53B	7.22B	6.83B	7.07B	8.52B	8.00B	8.92B	11.10B	9.80B	8.09B	5.09B	-21.00M	-	-1.86B	-1.97B	-2.07B	-2.17B
Shares Outstanding	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	277.00M	278.41M	279.00M	280.00M

Cash Flows (Annual)

Figures in USD.

Metric	Mar 2008	Mar 2009	Mar 2010	Mar 2011	Mar 2012	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Operating Cash Flow	869.00M	1.35B	2.32B	2.34B	2.95B	2.48B	3.14B	3.11B	3.67B	4.74B	4.34B	4.04B	4.37B	4.54B	-	5.16B	4.31B	6.08B	6.16B
Investing Cash Flow	-5.00M	-727.00M	-309.00M	-624.00M	-1.50B	-2.21B	-5.05B	-677.00M	-1.56B	-3.27B	-2.99B	-1.38B	-579.00M	-415.00M	-	-542.00M	-1.07B	-733.00M	-3.43B
Financing Cash Flow	-1.47B	178.00M	-421.00M	-1.84B	-1.91B	-956.00M	3.62B	-968.00M	-3.45B	-2.07B	-3.08B	-2.23B	-2.73B	-1.69B	-	-4.37B	-3.34B	-3.96B	-4.63B
Capital Expenditure	-195.00M	-195.00M	-199.00M	-233.00M	-221.00M	-241.00M	-278.00M	-376.00M	-488.00M	-404.00M	-405.00M	-426.00M	-362.00M	-451.00M	-	-558.00M	-687.00M	-859.00M	-745.00M
Free Cash Flow	674.00M	1.16B	2.12B	2.10B	2.73B	2.24B	2.86B	2.74B	3.18B	4.34B	3.94B	3.61B	4.01B	4.09B	-	4.60B	3.63B	5.23B	5.41B
Net Change in Cash	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	719.00M	-100.00M	1.39B	-1.91B
Share Buybacks	-	-	323.00M	2.05B	1.87B	1.21B	130.00M	450.00M	1.61B	2.31B	1.71B	1.64B	1.93B	742.00M	3.52B	3.64B	3.02B	3.15B	4.75B
Dividends Paid	70.00M	116.00M	131.00M	171.00M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

Ratios (Annual)

Figures in %.

Metric	Mar 2008	Mar 2009	Mar 2010	Mar 2011	Mar 2012	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Gross Margin %	-	-	-	-	-	-	-	-	-	5.7%	5.4%	5.5%	5.2%	5.1%	-	4.5%	4.2%	3.7%	3.6%
Operating Margin %	-	-	-	-	-	-	-	-	-	3.6%	0.4%	0.4%	1.1%	-2.1%	-	1.7%	1.4%	1.3%	1.6%
Net Margin %	-	-	-	-	-	-	-	-	-	2.6%	0.0%	0.0%	0.4%	-1.9%	-	1.3%	1.0%	0.9%	1.2%
ROE %	-	13.3%	16.8%	16.6%	20.5%	18.9%	14.8%	18.4%	25.3%	45.7%	0.7%	0.4%	17.7%	21,614.3%	-	-191.7%	-152.3%	-158.9%	-219.2%
ROCE %	-	12.4%	18.0%	15.0%	18.6%	17.5%	11.0%	14.6%	16.5%	28.1%	3.2%	4.0%	13.4%	-24.1%	-	31.9%	27.6%	35.6%	42.2%

Shareholding Pattern

Insiders

0.06%

Institutions

93.50%

Public Float

93.57%

Top Institutional Holders

#	Holder	% Held	Shares	Value
1	Blackrock Inc.	9.50%	11.42M	$8.48B
2	Vanguard Capital Management LLC	6.62%	7.96M	$5.91B
3	State Street Corporation	4.77%	5.73M	$4.26B
4	FMR, LLC	3.00%	3.60M	$2.68B
5	JPMORGAN CHASE & CO	2.72%	3.27M	$2.43B
6	Franklin Resources, Inc.	2.55%	3.06M	$2.27B
7	Geode Capital Management, LLC	2.42%	2.90M	$2.16B
8	Massachusetts Financial Services Co.	2.41%	2.90M	$2.15B
9	Vanguard Portfolio Management LLC	2.40%	2.88M	$2.14B
10	Morgan Stanley	1.91%	2.30M	$1.71B

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for MCK

No recent headlines available.

MCK · Healthcare